Renal response achieved with add-on belimumab in patients with LN in real-life setting
Among the 91 patients with lupus glomerulonephritis who received add-on belimumab in a real-life setting who met the study criteria, 70.3% (n = 64) achieved primary efficacy renal response (PERR), of which 38.4% achieved complete renal response during a median follow-up period of 22 months. The majority (86.7%) of patients who reached PERR by 6 months maintained the response through the study period.
Hypertension, high baseline serum, and high baseline proteinuria negatively predicted PERR according to multivariable analysis.
Baseline anti-Sm positivity and PERR at 6 months were positive predictors of PERR at 12 and 24 months.
Gatto M, Saccon F, Andreoli L, et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. J Autoimmun. 2021;124:102729. doi: 10.1016/j.jaut.2021.102729. Epub ahead of print. PMID: 34600347.